News
Zacks Investment Research on MSN2d
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 EarningsPfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...
Zacks Investment Research on MSN10d
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback